Aethlon Medical (NASDAQ:AEMD) Stock Passes Below 200 Day Moving Average – Time to Sell?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $7.21 and traded as low as $2.75. Aethlon Medical shares last traded at $3.01, with a volume of 126,199 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Aethlon Medical presently has an average rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Price Performance

The company has a market capitalization of $2.92 million, a PE ratio of -0.13 and a beta of 1.60. The company’s fifty day moving average is $3.21 and its 200-day moving average is $7.21.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Wednesday, November 12th. The medical equipment provider reported ($3.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.70) by ($2.04). Equities research analysts forecast that Aethlon Medical, Inc. will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is currently owned by hedge funds and other institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.